<DOC>
	<DOC>NCT03051087</DOC>
	<brief_summary>to compare and evaluate the efficacy and safety of Ganilever PFS and Orgalutran® in infertility women for assisted reproductive technologies</brief_summary>
	<brief_title>To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®</brief_title>
	<detailed_description />
	<mesh_term>Ganirelix</mesh_term>
	<criteria>An adult female between the ages of 20 and 39 at the time of screening Patients whose mean menstrual cycle was between 25 and 35 days Patients whose FSH (follicle stimulating hormone) concentration does not exceed 13 mIU / mL at screening Patients diagnosed with infertility due to one or more of the following A. Trouble Factors B. Male Factors C. Unexplained D. Uterine factors Patients with previous IVF experience less than 3 Patient who signed the written consent after hearing the explanation of the purpose, method and effect of the clinical trial If the sperm donor (spouse or nonspouse) is a severe male factor (Non obstructive azoospermia) Patients who were diagnosed as PCOS (polycystic ovary syndrome) during screening Patient with abnormal uterine bleeding during screening Patients diagnosed with primary ovarian failure Patients who has ovarian cysts that are not related to PCOS during screening Patients with tubal hydrops Patients with untreated nonreproductive endocrine disease Patients with a deformity of the reproductive organs that can not be conceived, or fibroids of the uterus that can not be conceived (only for submucosal myoma) Patients with less than 2 ovaries (0 or1) Patients with ovarian, breast, uterus, hypothalamus, or pituitary malignancies Patients with BMI &lt;18 or BMI&gt; 30 Patients with an LH concentration of less than 1.2mIU / mL during screening Poor ovarian responder by bologna criteria Patients with moderate or severe renal impairment (creatinine clearance &lt;60 mL / min) or liver function impairment (ALT or AST,&gt; 5 times normal) Patients who experienced Grade 4 or higher OHSS (ovarian hyperstimulation syndrome) before Patients who are contraindicated for pregnancy Patients being pregnant or lactating Patients with hypersensitivity to IP Patients who have participated in other medicationrelated clinical trials since enrollment in this study, or have participated in other clinical trials within 3 months (90 days) before enrolling in this trial</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>